Aclarion Inc (ACON) - Total Liabilities
Based on the latest financial reports, Aclarion Inc (ACON) has total liabilities worth $699.75K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Aclarion Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Aclarion Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Aclarion Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Aclarion Inc.
Aclarion Inc Competitors by Total Liabilities
The table below lists competitors of Aclarion Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Strategic Equity Capital Closed Fund
LSE:SEC
|
UK | GBX329.00K |
|
CanadaBis Capital Inc
V:CANB
|
Canada | CA$16.64 Million |
|
GEMINA LABS LTD
F:8I7
|
Germany | €6.25 Million |
|
Bohra Industries Limited
NSE:BOHRAIND
|
India | Rs62.65 Million |
|
Ngenic AB
ST:NGENIC
|
Sweden | Skr65.29 Million |
|
CBEYOND
F:C5B
|
Germany | €400.03K |
|
McLaren Resources Inc
F:3ML
|
Germany | €355.91K |
|
Central China Real Estate Limited
F:AJ5
|
Germany | €103.47 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Aclarion Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Aclarion Inc (ACON) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aclarion Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aclarion Inc (2019–2024)
The table below shows the annual total liabilities of Aclarion Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.15 Million | -63.82% |
| 2023-12-31 | $3.19 Million | +362.89% |
| 2022-12-31 | $688.67K | -90.96% |
| 2021-12-31 | $7.62 Million | -9.03% |
| 2020-12-31 | $8.38 Million | +167.38% |
| 2019-12-31 | $3.13 Million | -- |
About Aclarion Inc
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom softwa… Read more